Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 362.34M | 416.14M | 403.69M | 368.04M | 333.54M |
| Total Receivables | 244.38M | 271.72M | 283.97M | 308.85M | 272.34M |
| Inventory | 93.83M | 82.48M | 129.31M | 162.18M | 175.11M |
| Prepaid Expenses | 16.14M | 9.51M | 8.98M | 11.77M | 16.71M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 11.04M | 9.10M | 7.96M | 9.13M | 13.73M |
| Total Current Assets | 727.72M | 788.95M | 833.90M | 859.97M | 811.43M |
|
|
|||||
| Total Current Assets | 727.72M | 788.95M | 833.90M | 859.97M | 811.43M |
| Net Property, Plant & Equipment | 17.77M | 19.04M | 20.44M | 20.16M | 19.19M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 61.80M | 77.06M | 47.53M | 24.35M | 1.31M |
| Total Assets | 807.29M | 885.05M | 901.87M | 904.48M | 831.93M |
|
|
|||||
| Total Accounts Payable | 55.29M | 38.57M | 42.73M | 38.27M | 26.79M |
| Total Accrued Expenses | 116.15M | 140.18M | 139.84M | 122.78M | 101.40M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 6.94M | 6.75M | 6.79M | 6.21M | 6.26M |
| Total Finance Division Other Current Liabilities | -- | -- | 1.90M | 1.90M | 80.85M |
| Total Other Current Liabilities | -- | -- | 1.90M | 1.90M | 80.85M |
| Total Current Liabilities | 178.38M | 185.51M | 191.26M | 169.17M | 215.29M |
|
|
|||||
| Total Current Liabilities | 178.38M | 185.51M | 191.26M | 169.17M | 215.29M |
| Long-Term Debt | 453.42M | 452.83M | 452.25M | 457.21M | 93.11M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 9.19M | 10.20M | 11.41M | 11.09M | 9.77M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 2.08M | 7.97M | 9.83M | 2.69M | 247.08M |
| Total Liabilities | 643.07M | 656.51M | 664.75M | 640.16M | 565.25M |
|
|
|||||
| Common Stock & APIC | 3.29B | 3.27B | 3.24B | 3.21B | 3.17B |
| Retained Earnings | -3.13B | -3.04B | -3.00B | -2.94B | -2.90B |
| Treasury Stock & Other | -3.05M | -3.31M | -3.14M | -3.36M | -3.53M |
| Total Common Equity | 164.22M | 228.54M | 237.12M | 264.33M | 266.68M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 164.22M | 228.54M | 237.12M | 264.33M | 266.68M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 164.22M | 228.54M | 237.12M | 264.33M | 266.68M |
|
|
|||||